# A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

> **NCT03922477** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 13 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Hu5F9-G4

## Key facts

- **NCT ID:** NCT03922477
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-08
- **Primary completion:** 2020-11-03
- **Final completion:** 2020-11-03
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The Sponsor decided to discontinue the development of atezolizumab in combination with magrolimab in the AML indication.
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922477, "A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03922477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*